successfully treat sudden and recurrent left-ear hearing loss, respectively, following a second dose of the BNT162b2 COVID-19; successfully treat sudden and recurrent left-ear hearing loss, respectively, following a second dose of the BNT162b2 COVID-19; The initial case was missing the following minimum criteria: unidentifiable patient. Upon receipt of follow-up information on13Jul2022, this case now contains all required information to be considered valid.  This is a literature report.  A male patient in his 20's received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Intralabyrinthine schwannoma" (ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 mrna vaccination (DOSE 1, SINGLE), for Covid-19 immunization.The following information was reported: DEAFNESS (medically significant), DISEASE RECURRENCE (medically significant), all with latency 1 day after the suspect product(s) administration, outcome "recovered" and all described as "successfully treat sudden and recurrent left-ear hearing loss, respectively, following a second dose of the BNT162b2 COVID-19". The patient underwent the following laboratory tests and procedures: Audiogram: On day 26 Tympanogram exhibited a, notes: normal bilateral type A pattern and masked bone conduction; On day 44 leading to, notes: impaired left ear hearing from most of the frequency range; On day 60 indicated a, notes: progressive sensorineural hearing loss of the left ear for low frequency compared with the normal right ear, with a marginal decrease in word discrimination (%), using the W-22 wordlist in the audio tests; On day 103 result showed, notes: progressive left ear hearing loss along with left ear ringing and mild vertigo; On day 111 the hearing, notes: test revealed an average of 20 dB improvement in the left ear hearing; On day 138 resulting in a, notes: significant hearing recovery and word recognition score back to normal, shown by a hearing test; On day 252 showed a, notes: stable result similar as Audio 6 verifying the long-term improvement on the hearing; Blood pressure measurement: Unknown result; Blood test: Normal; Electronystagmogram: On day 76 result showed that, notes: the left ear had 93% weakness in the caloric testing and 50% directional preponderance to the right; Full blood count: Normal; Lipids: Normal; Magnetic resonance imaging: On day 94, identifying a, notes: mass of about 6 x 4 mm labyrinthine schwannoma in the left vestibule.The images also revealed a reduction in the left side endolymph fluid.Thus, an internal labyrinthine schwannoma in the left side vestibule with extension into both the superior and lateral semicircular canals was detected; Metabolic function test: Normal; Opticokinetic nystagmus tests: displayed asymmetrical optokinetics, notes: and decreased intensity for the left side compared with the right side; Rheumatoid factor: Normal, notes: results without detection of autoimmune response; SARS-CoV-2 antibody test: Positive, notes: detected after vaccination; Vital signs measurement: Normal. Therapeutic measures were taken as a result of deafness, disease recurrence.; Sender's Comments: As per available information the causality of the event deafness and disease recurrence with the suspect product BNT162B2 can not be ruled out.